Cite
HARVARD Citation
Gambacorti‐Passerini, C. et al. (2022). Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. American journal of hematology. 97 (8), pp. E296-E298. [Online].